AEMD Interesting new hire. A Google search reveals Jeff Richardson as the primary media contact for Amgen a few years back:
Aethlon Appoints Senior Director of Communications
Tuesday December 6, 12:52 pm ET
SAN DIEGO--(BUSINESS WIRE)--Dec. 6, 2005--Aethlon Medical, Inc. (OTCBB:AEMD - News), a company pioneering the development of medical devices to treat infectious disease, announced today that Jeffrey Richardson has been appointed Senior Director, Communications. Mr. Richardson brings nearly 20 years of senior leadership in global public relations for research-based medical companies. Prior to joining Aethlon, Mr. Richardson was Director, Global Public Relations for Amgen, the world's largest biotechnology company. Previously, he held senior communications positions with both Glaxo and DuPont. Mr. Richardson will be responsible for establishing government and military communication initiatives and will manage medical industry and investor relations programs.
About Aethlon Medical
Aethlon Medical is pioneering the development of immunotherapeutic devices able to mimic the immune response of clearing viruses and viral toxins from circulation. The Company's lead product, the Hemopurifier(TM), converges the established principals of hemodialysis and affinity chromatography with the discovery of compounds that effectively adhere to the surface of a multiple envelope viruses. The Hemopurifier(TM) is targeted to treat acute and chronic infectious diseases, including, drug and vaccine resistant Biological Weapons, the Human Immunodeficiency Virus (HIV), and the Hepatitis-C Virus (HCV). The Company has an experienced management team, which receives support and guidance from globally recognized science and regulatory advisors representing the infectious disease, biowarfare, and dialysis industries. More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at www.aethlonmedical.com. |
